Sign in to continue:

Saturday, March 7th, 2026

BlackRock Sells Over 3 Million ENN Energy Shares During Privatisation Scheme Disclosure (March 2026)

BlackRock, Inc. Sells Over 3 Million Shares of ENN Energy Holdings Amid Privatisation Scheme

Major Shareholder BlackRock, Inc. Disposes of 3 Million Shares in ENN Energy Holdings

Key Highlights from the Public Disclosure Form (5 March 2026)

  • Date of Transaction: 4 March 2026
  • Seller: BlackRock, Inc. (A significant institutional investor, Class (6) associate)
  • Type of Transaction: Sale of shares
  • Number of Shares Sold: 3,035,205 ordinary shares
  • Sale Price per Share: \$69.95
  • Resultant Shareholding: 64,024,666 shares
  • Resultant Shareholding as a Percentage of Class: 5.6567%
  • Dealings Executed on: US exchange
  • Context: Occurred during a privatisation by way of scheme of arrangement for ENN Energy Holdings Ltd

Important Information for Shareholders

The recent sale of over 3 million shares in ENN Energy Holdings Ltd by BlackRock, Inc.—one of the largest institutional investors and a Class (6) associate of the company—could be highly significant for existing and potential shareholders. This transaction occurred at a price of \$69.95 per share, just as ENN Energy is undergoing a privatisation process via a scheme of arrangement.

Potential Price Sensitivity:

  • The transaction represents a substantial reduction in BlackRock’s holdings, reducing its ownership to approximately 5.66% of the company.
  • Such a large divestment by a major institutional investor during a privatisation process could signal changing sentiment towards the potential outcome of the privatisation or the perceived valuation of the shares.
  • The transaction was executed on the US exchange on behalf of discretionary investment clients, indicating international investor engagement and possibly reflecting global sentiment towards ENN Energy Holdings.

Shareholders should closely monitor:

  • Further disclosures or significant share movements by other key investors.
  • Any updates on the progress and terms of the privatisation scheme, as the actions of major shareholders can influence the scheme’s prospects and the share price.
  • Market reaction to this large-scale sale, as it could lead to increased volatility or shifts in trading volumes.

Detailed Transaction Summary

Party Date Type Shares Price/Share Resulting Balance % of Class Context
BlackRock, Inc. 4 March 2026 Sale 3,035,205 \$69.95 64,024,666 5.6567% Discretionary investment clients, US exchange, during privatisation

Investor Impact and Outlook

BlackRock’s significant reduction in its stake may be interpreted by the market as a lack of confidence in the upside potential of ENN Energy’s share price amid the ongoing privatisation. Alternatively, it may simply reflect portfolio rebalancing for certain clients. Nevertheless, the timing and scale of the transaction make it a potentially price-moving event that investors should not ignore.

Investors are urged to stay informed on any further disclosures, as well as official announcements regarding the privatisation scheme, as these could materially impact ENN Energy Holdings’ share valuation in the near term.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research or consult with a financial adviser before making investment decisions. Market conditions and company-specific developments can change rapidly and may affect share prices.


View ENN ENERGY Historical chart here



Public Disclosure of Securities Dealings in ENN Natural Gas Co., Ltd. by China International Capital Corporation Limited (March 2026)

Key Points for Investors China International Capital Corporation Limited (CICC), identified as an exempt principal trader connected with the Offeror, reported transactions in the A shares of ENN Natural Gas Co., Ltd. All dealings...

Hansoh Pharmaceutical’s Aumolertinib Mesylate Tablets Approved in EU as Monotherapy for Advanced EGFR-Mutated NSCLC 1

Hansoh Pharmaceutical Group – EU Approval for Aumolertinib Mesylate Tablets Hansoh Pharmaceutical Group Receives Landmark EU Approval for Aumolertinib Mesylate Tablets as Monotherapy in Advanced NSCLC Key Highlights for Investors European Union (EU) Approval:...

Upbest Group Limited Issues Clarification on Unauthorized Websites and Fraudulent Use of Subsidiary Names 1

Upbest Group Limited Issues Voluntary Clarification on Unauthorized Use of Its Subsidiaries’ Names Upbest Group Limited Issues Voluntary Clarification on Unauthorized Use of Its Subsidiaries’ Names Key Highlights for Investors: Upbest Group Limited (the...

   Ad